Caribou Biosciences Inc. (NASDAQ: CRBU) has experienced a rise in its stock price by 3.72 compared to its previous closing price of 5.65. However, the company has seen a gain of 1.74% in its stock price over the last five trading days. GlobeNewsWire reported 2023-08-29 that BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences:
Is It Worth Investing in Caribou Biosciences Inc. (NASDAQ: CRBU) Right Now?
Additionally, the 36-month beta value for CRBU is 1.98. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The public float for CRBU is 77.29M and currently, short sellers hold a 8.79% ratio of that float. The average trading volume of CRBU on September 18, 2023 was 3.41M shares.
CRBU’s Market Performance
The stock of Caribou Biosciences Inc. (CRBU) has seen a 1.74% increase in the past week, with a -8.86% drop in the past month, and a 27.39% gain in the past quarter. The volatility ratio for the week is 7.96%, and the volatility levels for the past 30 days are at 5.41% for CRBU. The simple moving average for the last 20 days is -3.48% for CRBU’s stock, with a simple moving average of -1.22% for the last 200 days.
Analysts’ Opinion of CRBU
Many brokerage firms have already submitted their reports for CRBU stocks, with Truist repeating the rating for CRBU by listing it as a “Buy.” The predicted price for CRBU in the upcoming period, according to Truist is $23 based on the research report published on July 11, 2023 of the current year 2023.
CRBU Trading at -10.24% from the 50-Day Moving Average
After a stumble in the market that brought CRBU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.57% of loss for the given period.
Volatility was left at 5.41%, however, over the last 30 days, the volatility rate increased by 7.96%, as shares sank -4.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.35% lower at present.
During the last 5 trading sessions, CRBU rose by +1.74%, which changed the moving average for the period of 200-days by -31.38% in comparison to the 20-day moving average, which settled at $6.06. In addition, Caribou Biosciences Inc. saw -6.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRBU starting from Rizvi Syed Ali-aamir, who sale 5,627 shares at the price of $6.31 back on Jan 19. After this action, Rizvi Syed Ali-aamir now owns 59,373 shares of Caribou Biosciences Inc., valued at $35,506 using the latest closing price.
Fischesser Ryan, the VP of Finance and Controller of Caribou Biosciences Inc., sale 10,000 shares at $10.80 during a trade that took place back on Oct 06, which means that Fischesser Ryan is holding 110,366 shares at $107,958 based on the most recent closing price.
Stock Fundamentals for CRBU
Current profitability levels for the company are sitting at:
- -768.17 for the present operating margin
- +73.71 for the gross margin
The net margin for Caribou Biosciences Inc. stands at -717.79. The total capital return value is set at -29.69, while invested capital returns managed to touch -27.79. Equity return is now at value -37.90, with -30.30 for asset returns.
Based on Caribou Biosciences Inc. (CRBU), the company’s capital structure generated 9.22 points at debt to equity in total, while total debt to capital is 8.44. Total debt to assets is 7.22, with long-term debt to equity ratio resting at 8.90. Finally, the long-term debt to capital ratio is 8.15.
When we switch over and look at the enterprise to sales, we see a ratio of 20.87, with the company’s debt to enterprise value settled at 0.17. The receivables turnover for the company is 2.17 and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.25.
Conclusion
In conclusion, Caribou Biosciences Inc. (CRBU) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
